Solvonis Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	May '21 May 31, 2021
Cash & Equivalents	1.72	0.76	0.16	1.64	0.04
Cash & Short-Term Investments	1.72	0.76	0.16	1.64	0.04
Cash Growth	127.21%	388.39%	-90.55%	4105.13%	56.00%
Accounts Receivable	0.2	0.06	0.11	0.33	0.09
Inventory	-	-	0.05	0.19	-
Total Current Assets	1.92	0.82	0.31	2.16	0.13
Net Property, Plant & Equipment	-	-	0.04	0.7	0.36
Other Intangible Assets	5.67	2.09	2.07	2.07	2.07
Other Long-Term Assets	-	0.3	0.01	0.01	0.01
Total Assets	7.59	3.2	2.43	4.94	2.57
Accounts Payable	0.48	0.12	0.25	0.32	0.67
Short-Term Debt	-	-	-	-	0.65
Current Portion of Leases	-	-	0.01	0	-
Unearned Revenue	-	-	0.09	0.04	-
Other Current Liabilities	-	-	0.03	-	-
Total Current Liabilities	0.48	0.12	0.39	0.37	1.32
Long-Term Debt	0.08	-	-	-	-
Long-Term Leases	-	-	0.02	0.02	-
Other Long-Term Liabilities	0.84	-	-	-	-
Total Long-Term Liabilities	0.91	-	0.02	0.02	-
Total Liabilities	1.39	0.12	0.41	0.39	1.32
Common Stock	6.74	2.23	0.04	0.04	0.01
Additional Paid-in Capital	13.37	9.86	10.9	10.36	3.44
Accumulated Other Comprehensive Income	-0.17	-	0.05	-0	-0.02
Retained Earnings	-16.3	-10.56	-8.97	-5.85	-2.19
Shareholders' Equity	6.19	3.08	2.03	4.55	1.25
Total Liabilities & Equity	7.59	3.2	2.43	4.94	2.57
Total Debt	0.08	0	0.03	0.02	0.65
Net Cash (Debt)	1.65	0.76	0.12	1.62	-0.62
Net Cash Growth	117.30%	525.62%	-92.52%	-	-
Net Cash Per Share	-	0.00	0.00	0.02	-0.01
Book Value	6.19	3.08	2.03	4.55	1.25
Book Value Per Share	0.00	0.00	0.02	0.04	0.02
Tangible Book Value	0.52	1	-0.04	2.49	-0.82
Tangible Book Value Per Share	0.00	0.00	-0.00	0.02	-0.01